The term ictal epileptic headache, instead of HE, should be used to define a migraine of epileptic origin in order to provide a framework for clinical diagnosis, investigation, and therapeutic approaches for each patient and to facilitate communication among clinicians.

Author Response: Zubeda Sheikh, East Rutherford; David Marks, Newark, NJ: We appreciate the comments of Belcastro et al. regarding our recent report. In the ICHD-3 classification, headaches secondary to seizures were classified as HE or postictal headache. Belcastro et al. suggested the term ictal epileptic headache for a headache that is the only ictal clinical manifestation of an epileptic seizure, is synchronous with the ictal EEG discharge, and responds to IV antiepileptic medications. Belcastro et al. differentiate an ictal epileptic headache from HE, which they propose as originally published. The authors regret the error.

CORRECTIONS

Antibiotic-associated encephalopathy
In the Views & Reviews article “Antibiotic-associated encephalopathy” by S. Bhattacharyya et al. (Neurology 2016;86:963–971), there is an error in the paragraph prior to “Limitations.” The last sentence should read “The use of iron, calcium, and aluminum supplements in patients with renal insufficiency can also alter gastrointestinal absorption of certain antibiotics such as quinolones” rather than “increase” as originally published. The authors regret the error.

Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study
In the article “Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study” by M.D. Zwan et al. (Neurology 2016;86:50–58), concordance was incorrectly defined in the Methods section. The correct definition is “the proportion of individuals with an identical classification of both biomarkers, e.g., normal CSF biomarkers (not Alzheimer-like) (either Aβ42 alone or Aβ42/tau) and normal (negative) amyloid-PET or abnormal (Alzheimer-like) CSF biomarkers (either Aβ42 alone or Aβ42/tau) and abnormal (positive) amyloid-PET.” In addition, the patient numbers described in the Results section under “Concordance between CSF Aβ42/tau ratio and amyloid-PET” are incorrect and should have been 140, 218, 39, and 17, respectively, as shown in table 5. The authors regret the errors.
Antibiotic-associated encephalopathy

Neurology 2016;86;2116
DOI 10.1212/WNL.0000000000002754

This information is current as of May 30, 2016

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/86/22/2116.1.full

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise

Neurology © is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2016 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.